Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Doxorubicin Liposome Injection in Recurrent Ovarian Cancer
NCT02260544Phase 1Completed
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Jul 2014
- Primary completion
- Apr 2015
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pegylated liposomal doxorubicin in ovarian epithelial cancer (2 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoints: Maximum Plasma Concentration at 58 days, Area Under the Curve (0-t) at 58 days and 1 more. Started Jul 2014; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
ovarian epithelial cancer
Beyond the preview
Go deeper on NCT02260544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260544.